Attached files
Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
(18 U.S.C. SECTION 1350)
In
connection with the Quarterly Report of Aeolus Pharmaceuticals,
Inc. (the “Company”) on Form 10-Q for the period ended
June 30, 2017, as filed with the Securities and Exchange Commission
on the date hereof (the “Report”), the undersigned,
John L. McManus, Principal Executive Officer of the Company, and
David Cavalier, Principal Financial and Accounting Officer of the
Company, each certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that, to the best of his knowledge:
1.
The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
2.
The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.
Date:
August 14, 2017
/s/
John L.
McManus
John L.
McManus
President
and Chief Executive Officer
(Principal
Executive Officer)
Date:
August 14, 2017
/s/ David Cavalier
David
Cavalier
Chairman,
Chief Financial Officer and Secretary
(Principal
Financial and Accounting Officer)
THIS
CERTIFICATION “ACCOMPANIES” THE QUARTERLY REPORT, IS
NOT DEEMED FILED WITH THE SEC AND IS NOT TO BE INCORPORATED BY
REFERENCE INTO ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED (WHETHER MADE BEFORE OR AFTER THE DATE OF THE QUARTERLY
REPORT), IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE
CONTAINED IN SUCH FILING. A SIGNED ORIGINAL OF THIS CERTIFICATION
HAS BEEN PROVIDED TO THE COMPANY AND WILL BE RETAINED BY THE
COMPANY AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR
ITS STAFF UPON REQUEST.